Pulmonary hypertension is classified into 5 groups based on its cause, according to the American Lung Association: This group includes idiopathic PAH, heritable PAH (due to genetic factors), and ...

Back to Healio In this episode, we dive into the early therapies and how our understanding of vascular physiology drastically changed the management of pulmonary hypertension.

I took the diet drug Redux in the late 1990s. It was pulled off the market due to correlated heart issues. I saw a cardiologist and learned that ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC) 3 or 4 at ...

Future Cardiol. 2013;9(3):335-349. The efficacy of ambrisentan was demonstrated in the concurrent ARIES-1 and -2 trials. [80] ARIES-1 randomized 202 patients with PAH to either placebo or ...

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking ...

In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension ...

Sotatercept, an activin signaling inhibitor, was associated with improved outcomes in patients with advanced pulmonary ...